Using imaging to predict responses to cancer treatment
Full project names:
- lmaging biomarkers of resistance in head and neck cancer: Usefultools to inform and guide treatment management
- Use of 89Zr based immune-PET to study immune checkpoint inhibitor (ICPI) therapy in head and neck cancer
In 2017, Oracle pledged funding to two exciting new research projects at The Institute of Cancer Research (ICR), being undertaken under the guidance of Dr Gabriela Kramer-Marek and Oracle Honorary Trustee, Professor Kevin Harrington.
In the projects, researchers will be investigating how clinicians can use state-of-the-art imaging techniques to look at a patient’s head and neck cancer and assess whether that patient will respond to treatment. Traditionally, treatment decisions are often based on biopsy specimens. However, we have learnt in recent years that this may not be an accurate reflection of the way that a patient’s disease will respond to treatment as different bits of the same tumour may have a slightly different genetic make-up – a phenomenon known as ‘intratumoural heterogeneity’. This means that treatments that work on one part of the tumour may not work on the whole tumour.
Dr Gabriela Kramer-Marek
Professor Kevin Harrington.
Dr Florian Raes, Julia Hobart
Length of project:
12 months +
The Institute of Cancer Research
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.